KORU Medical Systems, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 6, 2025 and accepted by EDGAR at Aug 6, 2025, 20:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $10.2m | us-gaap:Revenues |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $19.8m | us-gaap:Revenues |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $3.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $7.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-04-01 to 2025-06-30 | $6.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2025-01-01 to 2025-06-30 | $12.5m | us-gaap:GrossProfit |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $2.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-04-01 to 2025-06-30 | $5.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-01-01 to 2025-06-30 | $11.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$312.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-04-01 to 2025-06-30 | $17.4k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-01-01 to 2025-06-30 | $17.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$206.9k | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 46,193,709 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 46,088,353 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$697.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $472.3k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2025-06-30 | $8.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $17.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $25.5m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $6.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $9.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $16.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001161697-25-000217. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.